Monoamine metabolism in the cerebrospinal fluid in Parkinson's disease: relationship to clinical symptoms and subsequent therapeutic outcomes

Tohgi, Hideo; Abe, Takashi; Takahashi, Satoshi; Takahashi, Jun; Nozaki, Yuichi; Ueno, M.; Kikuchi, Toshihiro

doi:10.1007/bf02260911

Cited by 33 publications

(18 citation statements)

References 31 publications

(30 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…HVA is one of the main metabolites of dopamine in the CNS, and it may thus reflect the dopaminergic central function. There is general agreement in the literature about a decrease in the levels of CSF-HVA in patients with IPD (LeWitt et al, 1992), with a strong negative correlation with the motor disability and the duration of the disease (Tohgi et al, 1993;Chia et al, 1993;Espino et al, 1994). However, although CSF-HVA levels were lower in our patients than in controls, the difference was not significant.…”

Section: Discussioncontrasting

confidence: 56%

CSF somatostatin increase in patients with early parkinsonian syndrome

Espino¹,

Calopa²,

Ambrosio³

et al. 1995

J Neural Transm Gen Sect

View full text Add to dashboard Cite

Somatostatin-like immunoreactivity levels (SLI) in cerebrospinal fluid (CSF) were determined in twenty-three patients with untreated parkinsonian syndrome (15 with Idiopathic Parkinson's disease (IPD) and 8 with other forms of parkinsonism) at the moment of clinical diagnosis (mean duration of disease 1.1 +/- 0.2 years), and in 26 subjects without neurological symptoms. None of the IPD patients had a diagnosis of dementia at the moment of inclusion in the study. CSF-SLI content was found to be significantly higher in patients with parkinsonian syndrome (107.9 +/- 9.8 pg/ml) than in control subjects (73.5 +/- 8.4 pg/ml). The increase was also significant when controls were compared with IPD patients. In addition, a positive correlation between SLI and homovanillic acid was found in CSF of all patients. A test of learning memory was used to evaluate the mental state of patients and a significant increase in CSF-somatostatin levels was observed in patients with Idiopathic Parkinson's disease and severe affectation of memory. These results indicate that in the early steps of untreated parkinsonian syndrome, somatostatin concentration in cerebrospinal fluid may increase, probably due to the neurodegenerative depletion of somatostatin from striatal or cortical neurons.

show abstract

Section: Discussioncontrasting

confidence: 56%

CSF somatostatin increase in patients with early parkinsonian syndrome

Espino¹,

Calopa²,

Ambrosio³

et al. 1995

J Neural Transm Gen Sect

View full text Add to dashboard Cite

show abstract

“…Furthermore, the NE concentrations before treatment are predictive of the subsequent response of Hoehn and Yahr's stage and freezing of gait to dopamine agonists (Tohgi et al, 1993). These findings suggest that freezing of gait may be at least partly related to NE deficiency.…”

Section: Discussionmentioning

confidence: 97%

The effects of L-threo-3,4-dihydroxyphenylserine on the total norepinephrine and dopamine concentrations in the cerebrospinal fluid and freezing gait in parkinsonian patients

Tohgi

Abe

Takahashi

1993

J Neural Transm Gen Sect

Self Cite

View full text Add to dashboard Cite

We studied the effects of L-threo-DOPS (L-DOPS) on the concentrations of total (conjugated and unconjugated) dopamine (DA) and norepinephrine (NE) in the cerebrospinal fluid (CSF) of parkinsonian patients with freezing phenomenon. The NE concentration increased remarkably and dose-dependently after administration of L-DOPS in both L-dopa/carbidopa-pretreated and untreated patients. The DA concentration also increased mildly but significantly in L-dopa/carbidopa-untreated patients. Freezing phenomenon improved in 6 out of 8 patients at Hoehn and Yahr's stage III, and 1 out of 5 patients at stage IV. These results indicate that L-DOPS administration increases the NE concentration dose-dependently, and is effective for freezing of gait of moderate severity.

show abstract

“…There is a type A and type B enzyme in MAO, and the metabolism of DA is enzymatic. Striatal DA generation is restrained in Parkinson disease, and its metabolite, DOPAC, level decreases [14]. When the DA level is excessive or toxic, MAO-A Mean ± SD (n), ng/mg wet tissue.…”

Section: Discussionmentioning

confidence: 99%

Brain Catecholamine Alterations and Pathological Features with Aging in Parkinson Disease Model Rat Induced by Japanese Encephalitis Virus

et al. 2006

View full text Add to dashboard Cite

We analyzed two disease model groups with rats infected by Japanese encephalitis virus (JEV), a 90-day group and a 180-day group after JEV infection. The time measured by the modified pole test showed that motor activities in these two groups were slower than those of age-matched control groups. Striatal dopamine (DA) levels were significantly decreased in all JEV-infected rats. Norepinephrine concentration in brain regions in the 180-day group was significantly decreased in the medulla oblongata and hypothalamus as compared with the control and 90-day group. Tyrosine hydroxylase-positive neurons were significantly decreased in both JEV-infected rat groups. These results suggest that DA decrease and pathological changes in JEV-infected model rats persist for a long time, at least up to 180 days, and this model will be useful for the evaluation of new anti-parkinsonian agents.

show abstract

Monoamine metabolism in the cerebrospinal fluid in Parkinson's disease: relationship to clinical symptoms and subsequent therapeutic outcomes

Cited by 33 publications

References 31 publications

CSF somatostatin increase in patients with early parkinsonian syndrome

CSF somatostatin increase in patients with early parkinsonian syndrome

The effects of L-threo-3,4-dihydroxyphenylserine on the total norepinephrine and dopamine concentrations in the cerebrospinal fluid and freezing gait in parkinsonian patients

Brain Catecholamine Alterations and Pathological Features with Aging in Parkinson Disease Model Rat Induced by Japanese Encephalitis Virus

Contact Info

Product

Resources

About